Abstract: The advent of Artificial Intelligence (AI) has in just a few years invested multiple areas of knowledge, also affecting the medical-scientific sector. An increasing number of AI-based applications have been developed, among which conversational AI has emerged. Among these, ChatGPT has risen to the headlines, scientific and otherwise, for its distinct propensity to simulate a 'real' discussion with its interlocutor, based on appropriate prompts. Although several clinical studies using ChatGPT have already been published in the literature, very little has yet been written about its potential application in human pathology. We conduct a systematic review following the Preferred Reporting Items for Systematic Re-views and Meta-Analyses (PRISMA) guidelines, using PubMed and Scopus as databases, with the fol-lowing keywords: ChatGPT OR Chat GPT, in combination with each of the following: Pathology, di-ag-nostic pathology, anatomic pathology. A total of 90 records were initially identified in the literature search, of which 6 were duplicates. After screening for eligibility and inclusion criteria, only 5 publications were ultimately included. The majority of publications were original articles (n = 2), followed by case reports (n = 1), letter to the editor (n = 1) and review (n = 1). Although the premises are exciting and ChatGPT is able to co-advise the pathologist in providing large amounts of scientific data for use in routine microscopic diagnostic practice, there are many limitations that need to be addressed and resolved, with the caveat that an AI-driven system should always provide support and never a decision-making motive during the anatomo-pathological diagnostic process.

Background: There is poor evidence about sensitivity to chemotherapy according to microsatellite instability (MSI)/mismatch repair (MMR) status in endometrial cancer (EC). Methodology: The RAME study is a retrospective analysis aiming to assess response to chemotherapy in MSI-high (h) /deficient (d) MMR and MSI- low (l)/proficient (p)MMR EC patients. Primary endpoints were recurrence-free survival (RFS) for patients with localized disease and progression-free survival (PFS) and overall survival (OS) in patients with advanced/recurrent disease. Results: 312 patients treated between 2010-2022 in 4 high volume Multicenter Italian Trial in Ovarian cancer and gynecological malignancies (MITO) centers were selected. 239 patients had endometrioid EC (76.6%), 151 had FIGO stage I at diagnosis (48.9%) and 71 were MSI-h/dMMR (22.8%). Median age was 65 (range 31–91) years. Among patients with localized disease, median RFS was 100.0 months (95%CI 59.4–140.7) for MSI-l/pMMR and 120.9 months (60.0-181.8) for MSI-h/dMMR (p=0.39). Seventy-seven patients received first-line chemotherapy for advanced/recurrent disease. Patients with MSI-h/dMMR ECs had a significantly worse OS (p=0.039). In patients receiving platinum-based chemotherapy, no statistically significant difference in PFS (p=0.21) and OS (p=0.057) were detected, although PFS and OS were numerically longer in the MSI-l/pMMR population. Conclusion: Patients with metastatic MSI-h/dMMR EC receiving first-line chemotherapy had a significantly worse OS.